Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
10:55am, Monday, 04'th Nov 2024
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
07:00am, Friday, 01'st Nov 2024
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Wednesday, 30'th Oct 2024
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
07:00am, Monday, 28'th Oct 2024
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024
Best Momentum Stocks to Buy for October 24th
11:16am, Thursday, 24'th Oct 2024
FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
10:11am, Thursday, 24'th Oct 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, B
New Strong Buy Stocks for October 24th
08:31am, Thursday, 24'th Oct 2024
CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.
American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas
04:18pm, Monday, 21'st Oct 2024
WASHINGTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- American Citizens Abroad (ACA) has joined parties opposing actions which would narrow the ability of U.S. citizens living overseas to vote. In Pennsylvani
3 Attractive Biotechs With Recent Positives
04:17pm, Monday, 21'st Oct 2024
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term
10:55am, Monday, 21'st Oct 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
03:47pm, Friday, 18'th Oct 2024
Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Dise
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?
01:21pm, Friday, 18'th Oct 2024
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
11:36am, Friday, 18'th Oct 2024
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Friday, 18'th Oct 2024
From a technical perspective, Amicus Therapeutics, Inc. (FOLD) is looking like an interesting pick, as it just reached a key level of support. FOLD's 50-day simple moving average crossed above its 200
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44%
10:56am, Friday, 18'th Oct 2024
The consensus price target hints at a 43.4% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
